Drugs in Dev. Pulmonary/Respiratory Diseases
Phase I
Hong Kong 
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INS018_055 is the first anti-fibrotic small molecule inhibitor, generated by Insilico's Pharma.AI drug discovery platform, which targets major activated signaling cascades that significantly contribute to the pathogenesis idiopathic pulmonary fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : BHR Partners
Deal Size : $60.0 million
Deal Type : Series D Financing
Details : Capital raised in the round will further bolster Insilico's financial position and fuel the growth of its advancing pipeline, including its lead program ISM001-55 (INS018_055) which is currently in a Phase I study, and continued development of its Pharma...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 06, 2022
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : BHR Partners
Deal Size : $60.0 million
Deal Type : Series D Financing
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
Details : INS018_055 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2021
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ISM001-055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Insilico Begins First Human Trial of AI-Designed Fibrosis Drug
Details : Company intitates first-in-human microdose trial of ISM001-055, demonstrated highly promising results in multiple preclinical studies and significantly improved myofibroblast activation which contributes to the development of fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : ISM001-055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
